Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
- PMID: 18786258
- PMCID: PMC2592791
- DOI: 10.1186/ar2506
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
Abstract
Introduction: This trial evaluated the safety, biologic activity, and pharmacokinetics of belimumab, a fully human monoclonal antibody that inhibits the biologic activity of the soluble form of the essential B-cell survival factor B-lymphocyte stimulator (BLyS) in patients with systemic lupus erythematosus (SLE).
Methods: Seventy patients with mild-to-moderate SLE were enrolled in a phase I, double-blind, randomized study and treated with placebo (n = 13) or belimumab (n = 57) at four different doses (1.0, 4.0, 10, and 20 mg/kg) as a single infusion or two infusions 21 days apart. Patients were followed for 84 to 105 days to assess adverse events, pharmacokinetics, peripheral blood B-cell counts, serology, and SLE disease activity. Data from the study were summarized using descriptive statistics. chi2 type tests were used to analyze discrete variables. The Kruskal-Wallis test, the Wilcoxon test, and the analysis of covariance were used to analyze the continuous variables, as appropriate. The analysis was performed on all randomized patients who received study agent.
Results: The incidences of adverse events and laboratory abnormalities were similar among the belimumab and placebo groups. Belimumab pharmacokinetics were linear across the 1.0 to 20 mg/kg dose range. Long terminal elimination half-life (8.5 to 14.1 days), slow clearance (7 ml/day per kg), and small volume of distribution (69 to 112 ml/kg) were consistent with a fully human antibody. Significant reductions in median percentages of CD20+ B cells were observed in patients treated with a single dose of belimumab versus placebo (day 42: P = 0.0042; and day 84: P = 0.0036) and in patients treated with two doses of belimumab versus placebo (day 105: P = 0.0305). SLE disease activity did not change after one or two doses of belimumab.
Conclusions: Belimumab was well tolerated and reduced peripheral B-cell levels in SLE patients. These data support further studies of belimumab in autoimmune disorders.
Trial registration: ClinicalTrials.gov NCT00657007.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-5.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2592791/bin/ar2506-6.gif)
Similar articles
-
Belimumab for the treatment of systemic lupus erythematosus.Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29. Expert Rev Clin Immunol. 2015. PMID: 25543845 Review.
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613. Arthritis Rheum. 2011. PMID: 22127708 Free PMC article. Clinical Trial.
-
Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.Drugs Today (Barc). 2010 Dec;46(12):891-9. doi: 10.1358/dot.2010.46.12.1544336. Drugs Today (Barc). 2010. PMID: 21589946 Review.
-
Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study.Arthritis Rheum. 2010 Jan;62(1):201-10. doi: 10.1002/art.27189. Arthritis Rheum. 2010. PMID: 20039404 Free PMC article. Clinical Trial.
-
Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.Drugs R D. 2008;9(3):197-202. doi: 10.2165/00126839-200809030-00008. Drugs R D. 2008. PMID: 18457473
Cited by
-
The changing landscape of thyroid eye disease: current clinical advances and future outlook.Eye (Lond). 2024 Jun;38(8):1425-1437. doi: 10.1038/s41433-024-02967-9. Epub 2024 Feb 19. Eye (Lond). 2024. PMID: 38374366 Free PMC article. Review.
-
Infections in Patients with Systemic Lupus Erythematosus: The Contribution of Primary Immune Defects Versus Treatment-Induced Immunosuppression.Eur J Rheumatol. 2023 Oct;10(4):148-158. doi: 10.5152/eurjrheum.2023.23068. Eur J Rheumatol. 2023. PMID: 37850609 Free PMC article.
-
B Cell Tolerance and Targeted Therapies in SLE.J Clin Med. 2023 Sep 28;12(19):6268. doi: 10.3390/jcm12196268. J Clin Med. 2023. PMID: 37834911 Free PMC article. Review.
-
Co-Infection Talaromyces marneffei and Pneumocystis jirovecii in a Patient with Systemic Lupus Erythematosus.Infect Drug Resist. 2023 Jul 27;16:4913-4918. doi: 10.2147/IDR.S414763. eCollection 2023. Infect Drug Resist. 2023. PMID: 37534061 Free PMC article.
-
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy.Drugs. 2023 Apr;83(6):507-530. doi: 10.1007/s40265-023-01855-y. Epub 2023 Apr 5. Drugs. 2023. PMID: 37017915 Review.
References
-
- Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263. doi: 10.1126/science.285.5425.260. - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical